rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B
نویسندگان
چکیده
منابع مشابه
A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol
OBJECTIVE To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients. PATIENTS AND METHODS A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monothera...
متن کاملdetection of rtn236t mutation associated with adefovir dipivoxil resistance in hepatitis b infected patients with ymdd mutations in tehran.
background objectives: the risk of adefovir dipivoxil resistance emergence has increased in lamivudine-resistant hepatitis b infected patients. the mutations known as causing adefovir resistance, rtn236t and rta181v/t, are detected within the d and b functional domain of the hbv polymerase, respectively. in this study, we intended to determine the pre-existing adefovir-resistance mutations in p...
متن کاملHepatitis B virus with primary resistance to adefovir.
The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to te...
متن کاملMutations at Nucleotide 1762, 1764 and 1766 of Hepatitis B Virus X Gene in Patients with Chronic Hepatitis B and Hepatitis B-Related Cirrhosis
Abstract Background and objective: Hepatitis B virus (HBV) is a DNA virus with high tendency toward hepatic tissue. There are currently about 3 million HBV-infected people and 350 to 400 million chronic carriers of this virus in the world. X protein plays a role in the over-expression of oncogenes, carcinogenicity of liver cells and overlaps with the basal co...
متن کاملAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
BACKGROUND In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. METHODS We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Viral Hepatitis
سال: 2010
ISSN: 1352-0504,1365-2893
DOI: 10.1111/j.1365-2893.2010.01273.x